Board Member and CMO Exit ARS Pharma Amid Leadership Overhaul
SPRY is trading near its 52-week low of $6.66 (5.6% above the low).
Summary
Director Richard Lowenthal and CMO Sarina Tanimoto both left ARS Pharmaceuticals effective July 15. Lowenthal resigned from the board as a condition for severance under his employment agreement; Tanimoto was terminated without cause. The departures follow the June 24 news that Neffy failed to secure new commercial coverage, which sent shares down 23%, and the July 7 appointment of Donn Casale as CEO replacing Lowenthal. The simultaneous exit of a board member and the chief medical officer signals a deeper leadership reset. Severance includes prorated 2026 bonuses of $217,350 for Lowenthal and $111,780 for Tanimoto. No replacements were named.
At the time of this announcement, SPRY was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695.1M. The 52-week trading range was $6.66 to $18.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.